178974-59-9

Basic information

• Product Name: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)
• Synonyms: Benzenemethanol, 2-fluoro-3-methoxy- (9CI);2-Fluoro-3-methoxyBenzylalcohol;2-Fluoro-3-(hydroxymethyl)anisole;(2-fluoro-3-Methoxyphenyl)Methanol
• CAS NO: 178974-59-9
• Molecular Formula: C₈H₉FO₂
• Molecular Weight: 156.1542632
• Product Categories: HALIDE
• Mol File: 178974-59-9.mol

Chemical Properties

• Boiling Point: 254.1°Cat760mmHg
• Flash Point: 123.9°C
• Appearance: /
• Density: 1.187g/cm³
• Vapor Pressure: 0.00913mmHg at 25°C
• Refractive Index: 1.51
• CAS DataBase Reference: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(178974-59-9)
• EPA Substance Registry System: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(178974-59-9)

Safety Data

• Hazardous Substances Data: 178974-59-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
Benzenemethanol, 2-fluoro-3-methoxy(9CI) is utilized as a synthetic intermediate for the preparation of complex organic molecules. Its unique structure allows for the creation of a wide range of chemical entities, making it a versatile component in the synthesis of various compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Benzenemethanol, 2-fluoro-3-methoxy(9CI) is employed as a key component in the development of new drugs. Its incorporation into drug molecules can potentially enhance their therapeutic properties, leading to the discovery of novel pharmaceutical products with improved efficacy and safety profiles.
Used in Drug Synthesis:
Benzenemethanol, 2-fluoro-3-methoxy(9CI) is used as a building block in the synthesis of biologically active molecules. Its presence in drug molecules can contribute to their overall pharmacological activity, making it an essential part of the drug development process.
Safety Considerations:
It is important to handle Benzenemethanol, 2-fluoro-3-methoxy(9CI) with care due to its potential safety hazards. Proper safety measures should be implemented during its synthesis, storage, and use to minimize risks associated with its chemical properties.

InChI:InChI=1/C8H9FO2/c1-11-7-4-2-3-6(5-10)8(7)9/h2-4,10H,5H2,1H3

Upstream product

• 321-28-8 1-fluoro-2-methoxybenzene 
• 137654-20-7 2-fluoro-3-methoxybenzoic acid 
• 103438-88-6 2-fluoro-3-methoxybenzaldehyde 

Downstream Products

• 1202182-71-5 N-(2-fluoro-3-hexyloxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-69-1 N-(2-fluoro-3-pentyloxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-89-5 N-(3-(3-ethoxypropoxy)-2-fluorophenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-81-7 N-(2-fluoro-3-(4-methoxybutoxy)phenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-87-3 N-(3-(2-ethoxyethoxy)-2-fluorophenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-79-3 N-(2-fluoro-3-(3-methoxypropoxy)phenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-67-9 N-(3-butoxy-2-fluorophenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-85-1 N-(2-fluoro-3-(2-methoxyethoxy)phenyl)methyl-benzothiazole-6-carboxamide 
• 1146493-92-6 2-fluoro-3-hydroxybenzylamine hydrobromide 
• 1202182-65-7 N-(2-fluoro-3-propoxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-63-5 N-(3-ethoxy-2-fluorophenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-61-3 N-(2-fluoro-3-methoxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1143571-71-4 2-fluoro-3-methoxybenzylamine hydrochloride 
• 1143571-78-1 N-(2-fluoro-3-methoxyphenyl)methylphthalimide 

Relevant articles and documents

Synthesis method of elagolix intermediate

The invention relates to a synthesis method of an elagolix intermediate. Specifically, the invention provides a synthesis method of an elagolix intermediate compound X and an elagolix intermediate compound I. According to the method, 2-fluoro-3-methoxy-phenylacetic acid is used as a raw material, and the steps of cyclization, hydrolysis, amino protection, condensation, Mitsunobu reaction and the like are carried out in sequence, so that the elagolix intermediate compound X and the elagolix intermediate compound I are obtained. The method has the advantages of cheap and easily available reagents, high conversion rate, simple operation and low process cost, and is suitable for industrialization.

Unusual Kinetic Profiles for Lewis Base-Catalyzed Sulfenocyclization of ortho -Geranylphenols in Hexafluoroisopropyl Alcohol

The kinetic behavior of the Lewis base-catalyzed sulfenocyclization of polyenes in hexafluoroisopropyl alcohol (HFIP) was explored. The rate of reaction is not dependent on the electronic properties of the terminal nucleophile, suggesting that this captur

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4- tetrahydroisoquinoline derivatives as novel antihypertensive agents

A series of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized and their bradycardic activities were evaluated in isolated guinea pig right atria. Structure-activity relationship studies revealed that the introduction of an appropriate substituent and its position on the 1,2,3,4-tetrahydroisoquinoline ring are essential for potent in vitro activity. Furthermore, the tether between the piperidyl moiety and the terminal aromatic ring is important for potent antihypertensive activity. Oral administration of 6-fluoro-1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3, 4-tetrahydroisoquinoline (3b) to spontaneously hypertensive rats (SHR) elicited antihypertensive effects without inducing reflex tachycardia, which is often caused by traditional L-type Ca2+ channel blockers.

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

AMIDE COMPOUNDS AND USE THEREOF

An amide compound of the formula (I): wherein R1 represents a hydrogen atom or a fluorine atom and R2 represents a C1-C6 linear alkyl group or a linear (C1-C2 alkoxy)C2-C5 alkyl group, has an excellent controlling effect on a plant disease.

AMIDE COMPOUNDS AND USE THEREOF

An amide compound of the formula (I): wherein R1 represents a hydrogen atom or a fluorine atom and R2 represents a C3-C8 linear alkenyl group or C3-C8 linear alkynyl group, has an excellent controlling effect on a plant disease.

1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS

The invention relates to polysubstituted tetrahydronaphtalene derivatives of formula (I), to methods for the production thereof, and to their use as antiphlogistics. The substituents are defined in Claim 1.

PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid

Discovery of selective metal-binding peptoids using 19F encoded combinatorial libraries

A method for encoding solid-phase split/mix combinatorial libraries using the chemical shift of synthetic fluoroarenes ('F-codes') has been developed. They have wide chemical shift dispersion and are detectable at the sub-μmol level. 19F NMR is